Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.74−0.02 (-2.31%)
Close on Nov 18, 2026Market cap $250.67MP/E –Yield –
Ocugen net income
Net income is the profit left for shareholders after every expense, interest and tax.
Ocugen's net income for the twelve months ending Jun 30, 2026 was -$81.81M. For fiscal 2025 it was -$67.85M. The highest annual figure on record is -$16.21M in fiscal 2016.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$67.85M | – |
| FY2024 | Dec 31, 2024 | -$54.05M | – |
| FY2023 | Dec 31, 2023 | -$63.08M | – |
| FY2022 | Dec 31, 2022 | -$86.80M | – |
| FY2021 | Dec 31, 2021 | -$58.37M | – |
| FY2020 | Dec 31, 2020 | -$21.82M | – |
| FY2019 | Dec 31, 2019 | -$20.24M | – |
| FY2018 | Dec 31, 2018 | -$18.22M | – |
| FY2017 | Dec 31, 2017 | -$26.41M | – |
| FY2016 | Dec 31, 2016 | -$16.21M | – |
| FY2015 | Dec 31, 2015 | -$32.02M | – |
| FY2014 | Dec 31, 2014 | -$22.79M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.18M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.74M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.88M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.28M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$23.07M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.48M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.76M | – |
| Q2 FY2021 | Jun 30, 2021 | -$25.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.08M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.79M | -130.6% |
| Q3 FY2020 | Sep 30, 2020 | -$10.47M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.61M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.94M | – |
| Q4 FY2019 | Dec 31, 2019 | $12.38M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.77M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.54M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.31M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.96M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.29M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.04M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.80M | -175.0% |
| Q3 FY2017 | Sep 30, 2017 | -$6.00M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.54M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.08M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.06M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.32M | – |
See a number that looks wrong?